search
Back to results

Cerebral Cortical Influences on Autonomic Function

Primary Purpose

Healthy Subjects, Functional Dyspepsia, Irritable Bowel Syndrome

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
rTMS
Sponsored by
David Levinthal
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Healthy Subjects

Eligibility Criteria

21 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Adults between age 21 and 60
  • Participants without gastrointestinal symptoms (Healthy Subjects)
  • Participants with gastrointestinal symptoms compatible with functional dyspepsia (FD) and or irritable bowel syndrome (IBS)

Exclusion Criteria:

  • history of myocardial infarction, supplemental oxygen requirement, or diabetes
  • history of chronic gastrointestinal symptoms (for healthy subjects only)
  • history of gastric surgery
  • psychosis or altered cognitive status
  • history of head injury, metal in the skull, stroke, or a history of seizures
  • implantable devices, such as a pacemaker or nerve stimulator
  • current use of the following medications or use of substances which are known to lower the seizure threshold: amitriptyline (Elavil), nortriptyline (Pamelor), imipramine (Tofranil), doxepin (Sinequan), clozapine (Clozaril), chlorpromazine (Thorazine), amphetamines or methamphetamine, Ecstasy, Ketamine, Angel Dust/phencyclidine (PCP), cocaine, or 3 or more alcoholic drinks per day
  • pregnancy
  • Body-Mass-Index (BMI) > 35

Sites / Locations

  • University of Pittsburgh Medical CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Study subjects

Arm Description

At the baseline session, measures of autonomic activity (electrogastrogram - EGG, electrocardiogram - ECG, cardiac impedance - CI) will be monitored from about 15 minutes before up to 1 hour after consumption of a test meal, water or a nutrient drink. In addition, motor-evoked potentials (MEPs) elicited with paired pulse transcranial magnetic stimulation (ppTMS) will be assessed before and after the meal or drink. In subsequent sessions, repetitive transcranial magnetic stimulation (rTMS) is applied before the meal or drink. Based on responses to symptom surveys (IBS-SSS and PAGI-SYM), study subjects will be characterized as healthy or as having functional dyspepsia and/or IBS.

Outcomes

Primary Outcome Measures

Electrogastrogram (EGG)
The EGG will be analyzed in the frequency domain using fast Fourier Transformation (FFT). The power spectrum will be divided into frequency bands (normal gastric activity (~3 cycles per minute), slower than normal (bradygastria) and faster than normal (tachygastria)). rTMS-induced shifts in the power distribution across these frequency bands after consumption of water or a nutrient drink or a test meal will be compared to water or nutrient drink or test meal without rTMS.
Volume threshold to satiety
rTMS-induced shift in the volume of water or nutrient drink a subject can consume within a 5 min period before reaching satiety

Secondary Outcome Measures

MEP responses
rTMS-induced change in the amplitude of motor evoked potentials (MEP) elicited by paired pulse TMS
Heart rate variability
rTMS-induced change in heart rate variability elicited by Valsalva maneuver or diaphragmatic breathing
Cardiac Impedance
rTMS-induced change in cardiac impedance variability during Valsalva maneuver or diaphragmatic breathing

Full Information

First Posted
February 19, 2019
Last Updated
March 4, 2023
Sponsor
David Levinthal
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT03869372
Brief Title
Cerebral Cortical Influences on Autonomic Function
Official Title
Cerebral Cortical Influences on Autonomic Function
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 5, 2019 (Actual)
Primary Completion Date
January 2025 (Anticipated)
Study Completion Date
January 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
David Levinthal
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is an exploratory neurophysiological study that will determine the impact of non-invasive brain stimulation on autonomic regulation, with a focus on gastrointestinal function. These studies should provide a basis for future brain-based neurotherapeutic strategies in patients with functional GI disorders.
Detailed Description
The overall goal of this study is to determine the impact of non-invasive brain stimulation on autonomic function in human subjects without functional gastrointestinal disorders and in subjects with Irritable Bowel Syndrome (IBS) or Functional Dyspepsia (FD). Aim 1: Determine whether repetitive transcranial magnetic stimulation (rTMS) of specific cortical areas alters physiologic measures of gastrointestinal and cardiac function. The investigators will use rTMS to transiently induce changes in neural excitability within specific cortical regions identified as being linked to autonomic regulation. Based on preliminary neuroanatomical data, one of the leading candidate cortical areas associated with sympathetic regulation lies within the trunk representation of the primary motor cortex. Thus, the investigators first plan on targeting this region of the primary motor cortex with rTMS and assess the effect of various parameters of rTMS on gastrointestinal and cardiac function in healthy human subjects. The investigators will then perform additional experiments using rTMS targeted to other specific cortical sites, such as the dorsal premotor area and rostral cingulate cortex that have also been linked to autonomic control. Each of these identified cortical regions may make unique contributions to autonomic reactivity. Aim 2: Determine whether patients with functional gastrointestinal disorders demonstrate altered physiological reactivity to targeted rTMS. The investigators will use the optimal parameters of rTMS and regions of interest determined in Aim 1 to assess the gastrointestinal and cardiac reactivity in participants with functional dyspepsia (FD) and/or irritable bowel syndrome (IBS). These physiological responses will be correlated with assessments of disease severity, mood, and quality of life. --This study description has been revised since its original posting. Because all study procedures are performed in all subjects, regardless of being a healthy subject or one with FD and/or IBS, rather than a three arm trial, this trial should be regarded as having a single arm study design.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy Subjects, Functional Dyspepsia, Irritable Bowel Syndrome

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Subjects will act as their own controls: The investigators will assess measures of autonomic function at baseline and in response to various modes of TMS exposure.
Masking
None (Open Label)
Allocation
N/A
Enrollment
224 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Study subjects
Arm Type
Experimental
Arm Description
At the baseline session, measures of autonomic activity (electrogastrogram - EGG, electrocardiogram - ECG, cardiac impedance - CI) will be monitored from about 15 minutes before up to 1 hour after consumption of a test meal, water or a nutrient drink. In addition, motor-evoked potentials (MEPs) elicited with paired pulse transcranial magnetic stimulation (ppTMS) will be assessed before and after the meal or drink. In subsequent sessions, repetitive transcranial magnetic stimulation (rTMS) is applied before the meal or drink. Based on responses to symptom surveys (IBS-SSS and PAGI-SYM), study subjects will be characterized as healthy or as having functional dyspepsia and/or IBS.
Intervention Type
Device
Intervention Name(s)
rTMS
Intervention Description
In subsequent sessions, the same measures of autonomic activity and MEPs will be monitored but different patterns of repetitive TMS (rTMS) will be applied to motor cortex or other areas before the test meal, water or nutrient drink is consumed.
Primary Outcome Measure Information:
Title
Electrogastrogram (EGG)
Description
The EGG will be analyzed in the frequency domain using fast Fourier Transformation (FFT). The power spectrum will be divided into frequency bands (normal gastric activity (~3 cycles per minute), slower than normal (bradygastria) and faster than normal (tachygastria)). rTMS-induced shifts in the power distribution across these frequency bands after consumption of water or a nutrient drink or a test meal will be compared to water or nutrient drink or test meal without rTMS.
Time Frame
EGG will be monitored for 15 minutes before and up to 1 hour after consumption of the nutrient drink or the test meal
Title
Volume threshold to satiety
Description
rTMS-induced shift in the volume of water or nutrient drink a subject can consume within a 5 min period before reaching satiety
Time Frame
volumes will be determined immediately after the 5 min drinking window and compared across study sessions
Secondary Outcome Measure Information:
Title
MEP responses
Description
rTMS-induced change in the amplitude of motor evoked potentials (MEP) elicited by paired pulse TMS
Time Frame
before and up to 1 hour after rTMS
Title
Heart rate variability
Description
rTMS-induced change in heart rate variability elicited by Valsalva maneuver or diaphragmatic breathing
Time Frame
before and up to 1 hour after rTMS
Title
Cardiac Impedance
Description
rTMS-induced change in cardiac impedance variability during Valsalva maneuver or diaphragmatic breathing
Time Frame
before and up to 1 hour after rTMS

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adults between age 21 and 60 Participants without gastrointestinal symptoms (Healthy Subjects) Participants with gastrointestinal symptoms compatible with functional dyspepsia (FD) and or irritable bowel syndrome (IBS) Exclusion Criteria: history of myocardial infarction, supplemental oxygen requirement, or diabetes history of chronic gastrointestinal symptoms (for healthy subjects only) history of gastric surgery psychosis or altered cognitive status history of head injury, metal in the skull, stroke, or a history of seizures implantable devices, such as a pacemaker or nerve stimulator current use of the following medications or use of substances which are known to lower the seizure threshold: amitriptyline (Elavil), nortriptyline (Pamelor), imipramine (Tofranil), doxepin (Sinequan), clozapine (Clozaril), chlorpromazine (Thorazine), amphetamines or methamphetamine, Ecstasy, Ketamine, Angel Dust/phencyclidine (PCP), cocaine, or 3 or more alcoholic drinks per day pregnancy Body-Mass-Index (BMI) > 35
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Paul HM Kullmann, PhD
Phone
412-647-1533
Email
phmk@pitt.edu
First Name & Middle Initial & Last Name or Official Title & Degree
David J Levinthal, MD/PhD
Phone
412-303-0525
Email
levinthald@upmc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David J Levinthal, MD/PhD
Organizational Affiliation
University of Pittsburgh
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pittsburgh Medical Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
There is no current plan to share with specific individuals, but individual participant data and supporting information (below) that are the basis for the published results will be made available after de-identification.
IPD Sharing Time Frame
Beginning 3 months after article publication and up to 5 years thereafter.
IPD Sharing Access Criteria
Proposals to access trial data should be directed to the Principal Investigator (Dr. David Levinthal) at levinthald@upmc.edu, and if the researcher has a sound basis for the proposal, then requestors will be asked to sign a data access agreement (link to be determined).

Learn more about this trial

Cerebral Cortical Influences on Autonomic Function

We'll reach out to this number within 24 hrs